Astrazeneca Pharma India Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The approval is for an additional indication of Benralizumab 30 mg/ml solution for injection in a pre-filled syringe (brand name: Fasenra). The drug is now indicated for the treatment of patients aged 12 years and above with hypereosinophilic syndrome (HES) without an identifiable non-haematologic secondary cause.

The receipt of this permission paves the way for the marketing of Benralizumab 30 mg/ml solution for injection in a pre-filled syringe (brand name: Fasenra) in India for the specified additional indication, subject to receipt of related statutory approvals, if any.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.

The company?s standalone net profit declined 22.95% to Rs 44.88 crore in the quarter ended March 2026 as against Rs 58.25 crore during the previous quarter ended March 2025. Sales rose 20.42% to Rs 578.61 crore in the quarter ended March 2026 as against Rs 480.48 crore during the previous quarter ended March 2025.

The counter slipped 1.77% to Rs 8,092 on the BSE.

Powered by Capital Market - Live News

AstraZeneca Pharma India has appointed Praveen K Mittal, Director - Corporate Affairs, with effect from 06 July 2026

Astrazeneca Pharma India announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 36 per equity Share (i.e. 1800%) , subject to the approval of the shareholders.

Net profit of Astrazeneca Pharma India declined 22.95% to Rs 44.88 crore in the quarter ended March 2026 as against Rs 58.25 crore during the previous quarter ended March 2025. Sales rose 20.42% to Rs 578.61 crore in the quarter ended March 2026 as against Rs 480.48 crore during the previous quarter ended March 2025.

For the full year,net profit rose 62.02% to Rs 187.52 crore in the year ended March 2026 as against Rs 115.74 crore during the previous year ended March 2025. Sales rose 32.59% to Rs 2275.58 crore in the year ended March 2026 as against Rs 1716.29 crore during the previous year ended March 2025.

Powered by Capital Market - Live News